Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Neurodegener Dis. 2014;13(1):17-23. doi: 10.1159/000351096. Epub 2013 Sep 6.

MK886 reduces cerebral amyloid angiopathy severity in TgCRND8 mice.

Author information

1
Clinical and Experimental Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.

Abstract

BACKGROUND:

Deposition of amyloid-β (Aβ) in blood vessel walls as cerebral amyloid angiopathy (CAA) is observed in the majority of Alzheimer's disease (AD) brains. Inhibition of the 5-lipoxygenase (5-LOX) pathway has recently been suggested to play a role in reducing parenchymal Aβ deposition. However, products of the 5-LOX pathway also activate the peroxisome proliferator-activated receptor (PPAR) family, which promotes clearance of Aβ from the brain.

METHODS:

In the present study, we investigated the effect of MK886, a 5-LOX-activating protein (FLAP) inhibitor and PPARα antagonist, on CAA severity in TgCRND8 mice overexpressing the human Swedish and Indiana amyloid precursor protein mutations.

RESULTS:

We found that MK886 significantly reduced brain levels of nicastrin and PPARα, but did not affect levels of β-secretase, apolipoprotein E or low-density lipoprotein receptor-related protein-1. CAA severity and parenchymal plaque load was significantly decreased in both the cortex and hippocampus of mice treated with MK886 compared to control mice.

CONCLUSION:

These data suggest that 5-LOX and FLAP inhibitors may be useful in the treatment of CAA and AD.

PMID:
24021653
DOI:
10.1159/000351096
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center